Another trial, NCT03367715, investigated a combination of nivolumab (anti-PD-1), ipilimumab (anti-CTLA-4), and short-course radiation therapy in newly diagnosed MGMT-unmethylated GBM [41]. This evidence concerns the gene CTLA4 and glioblastoma.